TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11136909
Drug: During certoparin
Normalized name: certoparin
DrugBank: Certoparin (DB09261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During certoparin treatment
Study: 3312399
Drug: Thiothixene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiothixene (60 mg daily)
Study: 21741309
Drug: Dignity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity therapy
Study: 24728212
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin plus 2 g calcium daily until delivery
Study: 20173085
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg every 12 hours for 10 days
Study: 17658393
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg and Valsartan 320 mg
Study: 7589032
Drug: 0.075 mg
Normalized name: mestranol 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg gestodene and 0.03 mg ethinylestradiol
Study: 7589032
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg levonorgestrel and 0.03 mg ethinylestradiol
Study: 7589032
Drug: Both contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both contraceptive formulations
Study: 7589032
Drug: Post-treatment (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (1 month after last intake)
Study: 2107743
Drug: Hydralazine 50
Normalized name: hydralazine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 50 mg bid
Study: 2107743
Drug: Hydralazine 100
Normalized name: hydralazine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 100 mg bid
Study: 2107743
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg bid
Study: 293505
Drug: Randomized suppressive
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized suppressive therapy trial
Study: 22511916
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral FTC/TDF
Study: 29255900
Drug: Galcanezumab 300
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab 300 mg
Study: 26547351
Drug: Bicyclol combined
Normalized name: Bicyclol
DrugBank: Bicyclol (DB16014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicyclol combined with ganciclovir (bicyclol 3 mg/kg, twice daily; ganciclovir 5 mg/kg)
Study: 26547351
Drug: Ganciclovir alone
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir alone (5 mg/kg)
Study: 25618967
Drug: Chishaodanpi decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chishaodanpi decoction (CSDPD), 100 mL twice a day for 8 weeks, in addition to control treatment.
Study: 25618967
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment with potassium magnesium aspartate, diammonium glycyrrhizinate, glucurolactone, vitamin C, and lamivudine, once a day for 8 weeks.
Study: 25618967
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received treatment for 8 weeks.
Study: 22176384
Drug: Probiotics (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (exact dosage and duration not specified)
Study: 19998861
Drug: Daily journal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily journal
Study: 14748891
Drug: Levothyroxine (L‐T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L‐T4) treatment for 1 year
Study: 11302598
Drug: Morphine-infused silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-infused silver sulfadiazine cream
Study: 9631981
Drug: Maximally tolerated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximally tolerated oral therapy (diuretics, vasodilators, and digitalis)
Study: 9631981
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy at standard doses
Study: 5312248
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride (100 mg daily)
Study: 28423969
Drug: PULSE Program
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PULSE Program intervention (self-administered lifestyle intervention focused on weight loss, diet, and exercise)
Study: 26697487
Drug: Pharmaceutical Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical Intervention (PI) - information booklets, 30 min face-to-face medication education and psychological counseling by clinical pharmacists, 2 sessions per week for 2 months
Study: 26697487
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - conventional treatment only
Study: 21696849
Drug: Nutrilarm(®) capsules
Normalized name: NuTriaRX CreamPak KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrilarm(®) capsules (omega-3 and omega-6), twice a day for 6 months
Study: 21696849
Drug: Nutrilarm(®) capsules
Normalized name: NuTriaRX CreamPak KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrilarm(®) capsules
Study: 16254268
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (15 microg kg(‐1) h(‐1)) for 7 days
Study: 12968981
Drug: Liposomal daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal daunorubicin (Daunoxome) administered as a 1‐ to 2.5 h infusion with doses ranging from 30 to 60 mg m(‐2)
Study: 8941095
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary fiber intake (median, 34.8 g/d)
Study: 8941095
Drug: Low dietary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dietary fiber intake (median, 16.1 g/d)
Study: 1417428
Drug: Active imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active imipramine hydrochloride treatment maintained at an average dose of 200 mg
Study: 6433715
Drug: Sensory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensory stimulation therapy
Study: 29725702
Drug: Menthol Vuse
Normalized name: Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol Vuse Solo electronic cigarettes (14, 29, and 36 mg nicotine)
Study: 22399124
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg i.v. Magnesium
Study: 12355576
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid (ALA) as a topically applied photosensitizer for photodynamic therapy (PDT) with a fixed dose of ALA (200 mg/ml) and escalating radiant energies (50-150 J/cm(2)).
Study: 1568519
Drug: Sulodexide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (500 lipoproteinlipase releasing units twice daily for 1 month)
Study: 3917968
Drug: Parenteral amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amino acid-glucose solution for 1 month
Study: 3917968
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution without amino acids
Study: 3917968
Drug: Parenteral amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amino acid-glucose solution
Study: 12620945
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Anesthesia (GA) with propofol 2.5 mg x kg(‐1) and fentanyl 1 micro g x kg(‐1) maintained with N(2)O‐O(2) 50:50 and desflurane for 30 min
Study: 27222733
Drug: Dose counter
Normalized name: Qvar with Dose Counter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose counter adherence
Study: 21125461
Drug: Clazosentan 5
Normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clazosentan 5 mg/h
Study: 21125461
Drug: Clazosentan 15
Normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clazosentan 15 mg/h
Study: 17696126
Drug: Natalizumab 300
Normalized name: natalizumab 300 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 300 mg (n = 627)
Study: 17696126
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a plus natalizumab 300 mg (n = 589)
Study: 15877671
Drug: Subcutaneous darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous darbepoetin
Study: 15877671
Drug: Intravenous darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous darbepoetin
Study: 9796239
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anaesthesia with 8 mg of 0.5% hyperbaric bupivacaine
Study: 9796239
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with bilateral spinal anaesthesia using 15 mg of 0.5% hyperbaric bupivacaine
Study: 7638814
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (20 mg)
Study: 2533763
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg three doses by mouth)
Study: 2533763
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg three doses by mouth)
Study: 25126421
Drug: 6MHP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MHP vaccine
Study: 10701035
Drug: 1% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lignocaine 1.6 ml and 4 mg morphine
Study: 10701035
Drug: 1% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lignocaine 2 ml
Study: 21574837
Drug: GapSeal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: GapSeal gel
Study: 22374870
Drug: No prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No prednisolone treatment (Control)
Study: 2354694
Drug: gari as
Approvals — FDA: no, EMA: no, PMDA: no
Description: gari as eba 50 g
Study: 2354694
Drug: lafun 50
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lafun 50 g
Study: 2354694
Drug: parboiled cassava
Normalized name: cassava
Approvals — FDA: no, EMA: no, PMDA: no
Description: parboiled cassava flakes 76 g
Study: 26665746
Drug: Art Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art Therapy (AT) in addition to Psychotherapy (PT)
Study: 23980737
Drug: CET (Concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: CET (Concurrent Exercise Training)
Study: 19109574
Drug: Azathioprine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.0 mg/kg/day)
Study: 19109574
Drug: Methotrexate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (0.3 mg/kg/week, increased to 25 mg/week)
Study: 17146324
Drug: 4.5 mg.kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg.kg caffeine
Study: 17146324
Drug: 9.0 mg.kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.0 mg.kg caffeine
Study: 12710402
Drug: VaxGen vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VaxGen vaccine
Study: 10671332
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg orally twice daily)
Study: 3964534
Drug: Neat oil
Normalized name: neatsfoot oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neat oil suspension (Sandimmun)
Study: 29936921
Drug: Liquid ubiquinol
Normalized name: ubiquinol Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid ubiquinol (100 mg/d)
Study: 20393402
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg risedronate weekly, vitamin D, and calcium
Study: 15917045
Drug: Healthy Eating
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Eating and Lifestyle Program (10 weekly weight loss classes)
Study: 12526935
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day for 14 days
Study: 12526935
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg/day for 14 days
Study: 3190996
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 600 mg
Study: 3190996
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 1200 mg
Study: 3190996
Drug: Aspirin tablet
Normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin tablet 1200 mg
Study: 3190996
Drug: Aspirin tablets
Normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin tablets 600 mg
Study: 3190996
Drug: Aspirin tablets
Normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin tablets 900 mg
Study: 31891553
Drug: Interportal capsulotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interportal capsulotomy with closure (CC)
Study: 26552099
Drug: AllergiSense smartphone
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AllergiSense smartphone app and sensing system for injection training and feedback
Study: 25409596
Drug: Pexacerfont (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexacerfont (300 mg/day for 7 days, followed by 100 mg/day for 23 days)
Study: 25409596
Drug: Open-label pexacerfont
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label pexacerfont (same dosing regimen)
Study: 23994781
Drug: Tandem autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem autologous hematopoietic stem cell transplantation (auto-HSCT) followed by reduced-intensity conditioning (RIC) and allogeneic (allo)‐HSCT with bortezomib and donor lymphocyte infusions (group 1)
Study: 12127831
Drug: Appropriate care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate care with hylan G‐F 20 (AC+H)
Study: 12127831
Drug: Appropriate care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate care without hylan G‐F 20 (AC)
Study: 7988780
Drug: Glipizide treatment
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide treatment
Study: 2738213
Drug: Social problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social problem-solving therapy
Study: 791320
Drug: Phenobarbitone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (50 mg) 8-hourly for 3 weeks
Study: 791320
Drug: Orphenadrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orphenadrine (100 mg) 8-hourly for 3 weeks
Study: 791320
Drug: Chlorpromazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (100 mg) 8-hourly
Study: 20410233
Drug: Pasireotide 200-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 200-600 microg s.c. twice daily for 28 days
Study: 20410233
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 microg s.c. three times daily for 28 days
Study: 18765397
Drug: Darapladib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib (160 mg daily)
Study: 12501878
Drug: Cefpodoxime 200
Normalized name: cefpodoxime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime 200 mg BID
Study: 8524980
Drug: Diazepam (DZP)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZP) 5 mg
Study: 8524980
Drug: Diazepam (DZP)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZP) 10 mg
Study: 35214
Drug: Alcohol +
Normalized name: Benzyl alcohol + eucalyptus oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol + Clobazam 20 mg
Study: 25733676
Drug: Hypnotic medication
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic medication as an add-on treatment to a selective serotonin reuptake inhibitor
Study: 25733676
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as an add-on treatment to a selective serotonin reuptake inhibitor
Study: 22897785
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with cow's milk protein increased from 0.06 mg to a maximum of 6400 mg over 23 weeks.
Study: 22897785
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (control) receiving no active treatment.
Study: 21898715
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interpersonal psychotherapy and SSRI
Study: 10889153
Drug: r-metHuBDNF (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-metHuBDNF (100 microg/kg SC daily for 2 weeks)
Study: 10889153
Drug: r-metHuNT-3 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-metHuNT-3 (300 microg/kg SC thrice weekly for 2 weeks)
Study: 30118582
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen (1 g) + IV hydromorphone (0.5 mg)
Study: 30118582
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL normal saline) + IV hydromorphone (0.5 mg)
Study: 29152847
Drug: brexpiprazole +
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole + antidepressant therapy
Study: 29152847
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + antidepressant therapy
Study: 16103770
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitor regimens (lopinavir, indinavir, saquinavir, amprenavir at 50%, 32%, 11%, and 6% respectively)
Study: 16103770
Drug: Fold change
Normalized name: Folditam
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fold change (FC) and trough drug concentration (Cmin)
Study: 11855668
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg/day, p.o.) for 3 months
Study: 8606538
Drug: Diltiazem 300
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 300 mg once daily (n = 16)
Study: 8606538
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg once daily (n = 20)
Study: 268331
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral hygiene and no chewing (control)
Study: 8290186
Drug: 20-minute regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-minute regimen for labor augmentation
Study: 8290186
Drug: 40-minute regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-minute regimen for labor augmentation
Study: 1494489
Drug: Oxytocin (3-fold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (3-fold higher dosage)
Study: 152602
Drug: Muscimol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscimol treatment
Study: 30616657
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of ferric carboxymaltose (single dose)
Study: 30616657
Drug: 200 g/48
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g/48 h of iron sucrose (fractionated doses)
Study: 28239907
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 1200 mg/day
Study: 19485842
Drug: Biomarker-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-guided treatment strategies
Study: 19485842
Drug: Conventional test-guided
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional test-guided treatment strategies
Study: 17691581
Drug: Hydroxyl-chloroquine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyl-chloroquine (6 mg/kg per day), oral transfer agent liquid, Vit B1, Vit B2, Vit C, fish-liver oil, and pilocarpine (20 mg/d) for 2 months
Study: 15381891
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual without distraction
Study: 11433050
Drug: Sn-mesoporphyrin (SnMP)
Normalized name: Sn Mesoporphyrin
DrugBank: Stannsoporfin (DB04912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sn-mesoporphyrin (SnMP) administered as a single intramuscular dose of 6 micromol/kg birth weight within 24 +/- 12 hours of age
Study: 11433050
Drug: G‐6‐PD‐normal newborns
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐6‐PD‐normal newborns (control group)
Study: 11433050
Drug: G‐6‐PD‐deficient newborns
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐6‐PD‐deficient newborns (comparison group)
Study: 5297557
Drug: Danish BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danish BCG vaccine
Study: 5297557
Drug: Swedish BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish BCG vaccine
Study: 5297557
Drug: Czechoslovak BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Czechoslovak BCG vaccine
Study: 31655974
Drug: Ixekizumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (80 mg every 4 weeks or 12 weeks)
Study: 22334228
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and Metformin 1000 mg/day (D+M)
Study: 22334228
Drug: Diet, Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet, Metformin 500 mg/day and MYO 4 g/day plus 400 µg folic acid daily (D+M+I)